INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 439m ago
HOUSE PTR39m ago
SEC 13F38m ago
ROBINHOOD CHAIN38m ago
Public company

Annovis Bio, Inc.

ANVSCIK 0001477845

EDGAR filingsOpen in network
Price$0.84
1 year-58.6%
Disclosed transactions2
Buys / sells2 / 0
Max Insider Score50
Connections with evidence2

ANVS · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
50
HB
Hoffman Michael BDirector
ANVSAnnovis Bio, Inc.
Open-market purchase
BUY$5.00M
5.00M sh
Nov 6, 2026Nov 6, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 6, 2026
  • ← Insider ofevidence
    Hoffman Michael BDirector · Nov 6, 2026
traded Nov 6, 2026
+0d
SEC FORM 4

Evidence

41
HB
Hoffman Michael BDirector
ANVSAnnovis Bio, Inc.
Open-market purchase
BUY—
5.00M sh
Nov 6, 2026Nov 6, 2026
traded Nov 6, 2026
+0dSEC FORM 4

Evidence